Skip to contentK
Kyntra Bio, Inc.
K
KYNBKyntra Bio, Inc. Q2 2026 · 10-Q
Revenue-$1.47M-$1.47MN/M vs Q2 2025 Net Income$11.97M$11.97MN/M vs Q2 2025 EPS Diluted$2.96$2.96N/M vs Q2 2025 Operating Income-$17,574,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kyntra Bio, Inc. · CIK 921299 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$3,991,000N/M Margins · derivedOperating margin1192.3%+2086.3 pt vs Q2 2025
Net margin-812.3%−248.3 pt vs Q2 2025
ended Jun 30, 2026 · filed Aug 13, 2026 · 44 d after period end